EGRX Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) announced today that management will present at two investor conferences in June as follows:

             

Conference:

Jefferies 2017 Global Healthcare Conference

Date: Thursday, June 8, 2017
Time: 1:30 p.m. Eastern Daylight Time
Location: Grand Hyatt New York, NYC

Presenters:

Scott Tarriff, Chief Executive Officer, and David Pernock, President and Chief Commercial Officer

Webcast:

http://wsw.com/webcast/jeff105/egrx

             

Conference:

William Blair 37th Annual Growth Stock Conference

Date: Wednesday, June 14, 2017
Time: 1:20 p.m. Central Daylight Time
Location: Four Seasons Hotel, Chicago

Presenters:

David Pernock, President and Chief Commercial Officer, and David Riggs, Executive Vice President of Administration

Webcast:

http://wsw.com/webcast/blair53/egrx

 

The presentations will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the company’s website at www.eagleus.com, under the Investors Section.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

EN
31/05/2017

Underlying

EGRXEagle Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eagle Pharmaceuticals Inc.

 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BEND...

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. (“Blue Owl”) (the “Agreement”), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before ...

March 31, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockhol...

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved an amendment to its previously disclosed limited duration stockholder rights plan (the “Rights Plan”) to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in ful...

March 21, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financi...

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the appointment of Christopher Krawtschuk as Chief Financial Officer (“CFO”) of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk’s appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company’s board of directors. “Chris is a talented finance executive with deep exp...

November 12, 2024 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the “Company” or “Eagle”) (OTCMKTS: EGRX) today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights agreement (the “Rights Plan”), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company’s stockholders to have the opportunity to realize the long-term value of ...

October 31, 2024 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from...

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) serves as an...

August 27, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch